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Smoking is the largest preventable cause of morbidity and mortality in the world. 
Although there are effective pharmacologic and behavioral treatments for smoking 
cessation, our inability to objectively quantify smokers’ progress in decreasing smoking 
has been a barrier to both clinical and research efforts. In prior work, we and others have 
shown that DNA methylation at cg05575921, a CpG residue in the aryl hydrocarbon 
receptor repressor (AHRR), can be used to determine smoking status and infer cigarette 
consumption history. In this study, we serially assessed self-report and existing objective 
markers of cigarette consumption in 35 subjects undergoing smoking cessation therapy, 
then quantified DNA methylation at cg05575921 at study entry and three subsequent 
time points. Five subjects who reported serum cotinine and exhaled carbon monoxide 
verified smoking abstinence for the 3 months prior to study exit averaged a 5.9% increase 
in DNA methylation at cg05575921 (p < 0.004) over the 6-month study. Although the 
other 30 subjects did not achieve smoking cessation at the 6-month time point, their 
self-reported reduction of cigarette consumption (mean = 6 cigarettes/day) was associ-
ated with a 2.8% increase DNA methylation at cg05575921 (p < 0.05). Finally, a survey 
of subjects as they exited the study demonstrated strong support for the clinical use 
of epigenetic biomarkers. We conclude that AHRR methylation status is a quantifiable 
biomarker for progress in smoking cessation that could have substantial impact on both 
smoking cessation treatment and research.
Keywords: Dna methylation, epigenetics, aryl hydrocarbon receptor repressor, cg05575921, diagnostics, smoking 
cessation
inTrODUcTiOn
Smoking is the largest cause of preventable morbidity and mortality in the United States. Each 
year, nearly a half-million Americans die secondary to the effects of smoking (1). Still, nearly one 
in every five US adults currently smoke (2). Currently, three pharmacological agents, bupropion, 
varenicline, and nicotine replacement therapy (NRT), are commonly used for smoking cessation (3). 
By themselves, each of these medications is modestly effective and recent clinical trials suggest that 
the combination of varenicline and NRT is most effective in achieving cessation (3, 4). Nevertheless, 
the efficacy of these treatments in actual clinical practice has been less than optimal (5).
2Philibert et al. AHRR Provides Smoking Cessation Biomarker
Frontiers in Psychiatry | www.frontiersin.org April 2016 | Volume 7 | Article 55
Although many barriers to the effective implementation of 
these and smoking cessation interventions exist, one of the more 
difficult hurdles to overcome is our current inability to quantify 
decreases in smoking and the success of cessation therapy. In epi-
demiologic studies, self-report is generally accurate, however, in 
clinical populations, it is much less reliable (6–8). Currently, two 
biological methods are commonly used to determine the success 
of therapy and corroborate self-report: exhaled carbon monoxide 
(CO) and cotinine levels. Exhaled CO levels are perhaps the easi-
est assessments to perform. But this measure is only capable of 
detecting smoking in the past 3–4 h and is not useful in quali-
fying changes in smoking at these levels because it is relatively 
insensitive to light-to-moderate smoking (9, 10). By contrast, 
assessments of cotinine, which has a serum half-life of 15 h, are 
much more sensitive and can detect smoking in the past 48–72 h 
(11). However, because false positives can arise from other forms 
of tobacco consumption (second-hand smoke, e-cigarettes, and 
ironically, NRT use) its clinical utility in monitoring decreased 
smoking and abstinence is limited. In fact, since over one-fourth 
of all patients who successfully quit smoking using NRT remain 
on NRT for at least 1 year after smoking cessation (12), the effi-
cacy of employing cotinine levels to guide smoking cessation in 
clinical settings is minimal.
The development of quantitative continuous dose–response 
measures of decreases in smoking in therapy could significantly 
advance smoking cessation efforts in much the same way that 
the introduction of hemoglobin A1C (HbA1c) levels to assess the 
need and effectiveness of diabetes management has revolution-
ized the treatment of Type 2 diabetes (T2DM) (13). The use of 
HbA1c assessment, which is a measurement of the level of the 
acetylation of hemoglobin by serum glucose, allows clinicians 
to not only diagnose T2DM but also objectively quantify the 
progress of diabetic therapy. The latter is particularly important 
because numerous studies have shown that patients, in particular 
those who are at the highest risk, do not accurately report treat-
ment compliance (14). The same challenges confront clinicians 
dealing with smoking cessation, suggesting that if a similar tool 
for measuring smoking intensity could be developed, it is pos-
sible that clinicians could use that assessment to detect changes in 
smoking, and modify treatment strategies during therapy.
DNA methylation assessments may provide a tool that can 
accurately assess amount and changes in smoking status in 
order to track the trajectory of smoking initiation and cessation. 
Over the past 3  years, at least 20 studies have confirmed the 
initial findings that methylation at cg05575921, a CpG residue 
in the aryl hydrocarbon receptor repressor (AHRR), is the most 
sensitive indicator of smoking status at all levels of smoking (15, 
16). In particular, in a recent clinical trial, methylation status at 
this locus was employed to classify the smoking status of adult 
subjects, and was shown to be extremely accurate with a receiver 
operating characteristic (ROC) area under the curve (AUC) of 
0.99 (15). Whereas these and other studies clearly indicate that 
DNA methylation can be used to track changes in smoking, they 
have not addressed the question of whether DNA methylation 
could be used to guide smoking cessation therapy.
Several genome-wide studies, including work from Zeilinger 
and colleagues and Tsaprouni and colleagues have compared 
smokers’ and non-smokers’ methylation at specific loci and 
concluded that the smoking-induced DNA methylation signature 
reverts as a function of long-term abstinence with cg05575921 
being one of the most prominent loci demonstrating reversion 
(17, 18). In addition, however, Zeilinger et  al. estimated that 
the speed of that reversion was relatively slow, with a change of 
approximately 7% occurring over a course of 7 years. If this is cor-
rect, this would suggest that DNA methylation changes relatively 
slowly and could not be used for monitoring smoking cessation.
However, recent evidence has suggested that the speed of 
reversion of DNA methylation at cg05575921 may be significantly 
faster than that estimate. In our recent examination of alcoholic 
inpatients, those who smoked prior to admission but were either 
completely or partially deprived of cigarettes during their stay, 
averaged a 1.7% increase in CG05575921 over 25 days (19). 
Second, both the Zeilinger and Tsaprouni studies were cross-
sectional studies that employed self-report without biochemical 
verification of smoking status. Since the reliability of retrospective 
recall of smoking cessation is poor (20) and their study design did 
not allow before and after comparisons of individual subjects, the 
speed of methylation reversion in Zeilinger and Tsaprouni reports 
may be an underestimate. In this study, we directly examine the 
relationship between cigarette consumption status and DNA 
methylation at cg05575921 in a cohort of subjects undergoing 
smoking cessation therapy under the direction of their personal 
physicians.
MaTerials anD MeThODs
All methods and procedures used in this study were approved by 
the University of Iowa Institutional Review Board. In brief, the sub-
jects were recruited by direct advertising and word of mouth from 
University of Iowa affiliated clinical operations. Inclusion criteria 
for the screening of potential subjects for the study included the 
following: being a current active smoker who was getting ready to 
begin smoking cessation within 4 days of the intake appointment, 
and abstinence from any nicotine-containing product, including 
e-cigarettes. Please note that the rationale for exclusion of those 
subjects using other forms of nicotine-containing products was 
to allow the team to use cotinine assays to detect surreptitious 
smoking. Non-combustionable forms of tobacco consumption 
do not have an effect on cg05575921 levels (15, 21). Other exclu-
sion criteria included use of any medication thought to interfere 
with DNA methylation, such as methotrexate, and any active 
form of substance use with the exception of alcohol.
At intake, all subjects were interviewed with the Semi-
Structured Assessment for the Genetics of Alcoholism, Version 
2 (SSAGA-II) modified for use in our studies (22). Notably, 
the Fagerstrom Test for Nicotine Dependence (FTND) (23) 
is embedded within the interview. In addition, substance con-
sumption over key time frames was interrogated by a tailored 
substance use questionnaire described previously (19). Exhaled 
CO was assessed using a Tabataba CO Tester (Depisteo, France). 
Phlebotomy was then performed by a trained research assistant 
with sera being immediately separated via centrifugation, then 
stored at −80°C until use. Whole blood DNA was prepared 
TaBle 1 | clinical characteristics of the study completers.
Age 42.3 ± 13.5 years
Gender
Male 14
Female 21
Ethnicity
White 26
African Amer. 4
Hispanic 1
Other 3
Consumption at intake
Lifetime 16.3
Past month 11.3 cigarettes/day
rs16969968 genotype
GG 24
AG 15
AA 5
FTND score 3.7 ± 2.5
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using cold protein precipitation, quantified with a NanoDrop 
 photometer (ThermoFisher, Holtsville, NY, USA) and stored at 
−20°C until use (24).
Subsequently, each subject was assessed in person at 1, 3, and 
6 months after study intake. In addition, they were contacted via 
phone or e-mail at 2, four, and 5 months after study intake. At 
the in person visits, each subject was re-interviewed with the 
substance use questionnaire, interval health, and medication use, 
including the use of any nicotine-related products, and exhaled 
CO were assessed, and phlebotomy was performed. During the 
phone or e-mail contacts, subjects were interviewed with the 
substance use questionnaire. DNA and sera were prepared from 
the in person visits as described above.
DNA methylation status at cg05575921 was determined using 
quantitative PCR (qPCR) as previously described (25). In brief, 
whole blood DNA was bisulfite converted using Fast 96 Bisulfite 
Conversion kits (Qiagen, Valencia, CA, USA) according to manu-
facturer’s direction. Subsequently, cg05575921 methylation status 
of each sample was measured in quadruplicate using an ABI 
7900HT Genetic Analysis System (Applied Biosystems, foster 
city, CA, USA), qPCR reagents (both assay and standards) from 
Behavioral Diagnostics (Iowa City, USA), and standard. The SD 
of replicate measurements was 0.23 cycles. The average methyla-
tion value for each sample was then determined by interpolation 
against the standard curve (25).
Serum levels of cotinine and hydroxy tetrahydrocannabinol 
(THC-OH) was determined using kits from AbNova (Taiwan) 
according to manufacturer’s directions. Because the THC-OH 
kit does not come with internal standards suitable for the 
assessment of serum samples, a series of dilution of a methanol 
solution containing (±)-11-nor-9-carboxy-delta-9-THC (T-010, 
Sigma, Ronkonkoma, NY, USA) was used to quantify the extent 
of  cannabis use.
Genotype at rs16969968 was determined using a primer probe 
set and a 2X polymerase master mix from Applied Biosystems 
(Foster City, CA, USA) per our usual protocols (26).
All regression analyses were conducted using JMP Version 
10 (SAS Institute, Cary, SC, USA). For the main analysis, which 
examined the relationship between DNA methylation and smok-
ing cessation status, a least squares regression model stipulating 
DNA methylation as the independent variable and subject, time 
since initial quit date, and a subject × time interaction term as the 
dependent variables, was used.
resUlTs
A total of 47 subjects passed the initial screening for inclusion in 
the study. Subsequently, four of those subjects were disqualified 
from further continuation of study for revealing information, 
such as active cannabis use, during the intake interview that was 
incompatible with continuation in the study. In order to ascertain 
substance use and increase study retention, we attempted to con-
tact all remaining subjects monthly with the in person visits also 
serving as an opportunity to perform biochemical verification 
of smoking status. By and large, this strategy was successful in 
retaining 35 of the 43 (81%) subjects eligible to continue in the 
study participating in the 6-month visit.
The clinical characteristics of the 35 subjects who completed 
the 6-month study are given in Table 1. The subjects are mostly 
female (60%) of northern European ancestry (75%) and have an 
average age in their early 40s. They reported smoking an average 
of 11 cigarettes/day and had an average history of 16 pack years 
of smoking. Five reported use of bupropion; the remaining 30 
attempted to quit smoking without pharmaceutical assistance.
At each in person contact point, serum cotinine and exhaled CO 
were assessed. In keeping with prior findings, exhaled CO assess-
ments were less sensitive than cotinine levels for detecting smoking. 
For example, at the 6-month exit time point, nine subjects had CO 
of <10 ppm but still reported continued smoking and had serum 
cotinine levels supportive of continued smoking. Six of these nine 
reported daily smoking (between one and six cigarettes/day), while 
the three others reported continued periodic smoking (i.e., every 
other or every third day). In addition, one subject who reported 
59 days of abstinence had an undetectable level of cotinine regis-
tered a reading of 19 ppm, which is suggestive of a false positive.
Active cannabis use and/or continued use were both exclu-
sion criteria for the study. To examine the reliability of subjects 
with respect to this inclusion criterion, serum THC-OH levels, 
at intake and 1-month time points, were assessed. Two subjects, 
both of whom reported continued tobacco use at all study time 
points, had markedly positive serum THC-OH levels at the intake 
and 1-month study time points.
We defined successful smoking cessation as having self-
reported smoking cessation, and both negative serum cotinine 
and exhaled CO levels at the 3- and 6-month time points. Using 
these criteria, four subjects [tobacco cessation (TC) 24, 31, 41, and 
46] successfully quit smoking with a fifth (TC 28) having had only 
two cigarettes since quitting at study inception, 180 days prior, 
with all subjects giving serum and exhaled CO levels consistent 
with those reports. In addition, one subject who reported 59 days 
of abstinence had a negative cotinine at study exit, but not at the 
3-month time point. Finally, five other subjects reported smoking 
cessation at study exit. Unfortunately, each of those had exhaled 
CO levels >10 ppm and high levels of serum cotinine inconsistent 
with cessation.
FigUre 1 | a Plot of cg05575921 methylation as a function of time 
from smoking cessation intake/quit point. Percent methylation, as 
indicated by the qPCR assay, is given on the Y axis. Time (in months) of the 
blood draw relative to the inception of the subject into the study and 
hopefully their efforts to reduce smoking is given on the X axis. Each of the 
subjects had negative cotinine and exhaled CO levels at the 3- and 6-month 
time points. The linear fit of the reversion curve for each subject is denoted 
by the color in the figure legend. For example, the best fit line for tobacco 
cessation (TC) subject 31 (TC31) is shown in blue.
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We then analyzed the relationship between smoking cessation 
and cg05575921 methylation for the five subjects who had nega-
tive cotinine and CO levels at the 3- and 6-month interview visits 
using least squares regression. Figure 1 illustrates the results of 
those analyses. Not surprisingly, subject consumption history had 
the greatest effect on methylation levels (p < 0.0001) with TC 28 
and 31 having the highest initial methylation levels, the lowest 
levels of current smoking and the least history of smoking, 2 and 
4 pack years, respectively. In fact, the methylation level of TC 28 
returned to the range consistent with a lifetime history of non-
smoking by the end of the study (95%), while the level of TC 31 at 
study exit was nearly 89%. By contrast, although the methylation 
levels of TC 24 (15 pack years), TC 41 (20 pack years), and TC 
46 (15 pack years) increased as a function of TC, their values 
remained lower than those of the subjects with less smoking 
history, with methylation levels of 75, 47, and 77%, respectively. 
Still, the effect of time of cessation was clearly significant, i.e., 
increasing time since study intake being associated with increas-
ing cg05575921 methylation (p < 0.004).
In addition to the promising results shown for those in full 
cessation, examination of the DNA methylation from those 
subjects whose cotinine and exhaled CO data were not consistent 
with complete cessation at 6 months were also promising. In total, 
29 subjects did not have negative cotinine and CO levels at the 
3- and 6-month time points. In fact, with the exception of the sub-
jects listed above, only two other subjects had a negative cotinine 
level at either time (both at 3 months; but not at study exit). Still, 
as a whole, these subjects reported an average decrease in cigarette 
consumption of 5.8 cigarettes/day (11.3 cigarettes/day at intake 
and 5.5 cigarettes/day at 6-month exit). This decrease in smoking 
was accompanied by an increase in methylation from an average 
of 66.7 to 69.5% over the 6 months (Adj. R2 = 0.14, p < 0.05).
Prior work by ourselves and others has shown that cg05575921 
is associated with the quantity of cigarette consumption. To better 
understand how this consumption is linked to other factors, such 
as nicotine craving and key genetic variables, we conducted a 
series of regression analyses with methylation as the independ-
ent variable, and total history of smoking (pack years), current 
smoking, FTND, and rs16969968 genotype. Consistent with prior 
analyses, cg05575921 methylation at intake was associated both 
with current consumption (Adj. R2 = 0.37, p < 0.0002) and history 
of consumption (Adj. R2 = 0.34, p < 0.0004). In addition, a regres-
sion model that included FTND score and rs16969968 fitted to 
cg05575921 methylation was highly significant (Adj. R2 = 0.38, 
p < 0.001) with significant effects of FTND score (p < 0.0002) 
and a trend (p <  0.06) for an interaction between FTND and 
rs16969968 genotype but no main effect of rs16969968 genotype.
One critical question for the field is whether the use of epi-
genetic biomarkers will be accepted by patients. To examine this 
question, we conducted a voluntary exit survey of the attitudes 
of subjects after their sixth visit (Supplemental Table 1). Thirty 
three subjects agreed to fill out the survey. As a group, the 
subjects reported a high degree of commitment to smoking ces-
sation with nine indicating more modest commitment and one 
subject reporting a complete ambivalence to quitting smoking. 
Supporting prior assertions that dysfunctional patient-provider 
interactions may interfere with therapy, 10 of the 33 subjects 
indicated previous discomfort in answering physicians’ questions 
about their smoking habits. Finally, when queried with a 6-point 
Likert scale as to their interest in receiving data from a test that 
could inform them on their success in smoking cessation and risk 
for adverse cardiovascular outcomes, the response to receiving 
epigenetic feedback was overwhelming positive with all but one 
subject, indicating moderate to great interest (the average score 
on 0–5 scale was 4.3) in receiving epigenetic feedback.
DiscUssiOn
Before discussing these results, it is important to note some 
important limitations of this study funded under a National 
Institutes of Health pilot mechanism. First of all, the study cohort 
is small, largely White and drawn from the clinics of a tertiary 
care hospital. Further examinations using larger numbers of sub-
jects of all ethnicities and more representative treatment settings 
are required to demonstrate the generalizability of the findings. 
Second, although the proportion of subjects in this study using 
pharmacotherapy aid in their smoking cessation efforts is in keep-
ing with that in the general clinical population, in order to most 
rapidly advance the usefulness of this technique, examination of 
patient attitudes toward epigenetic biomarkers in state of the art 
treatment paradigms would be desirable to optimize potential 
impact of this technology.
Still, if the current results are replicated and extended, the 
clinical implementation of an epigenetic monitoring tool could 
have substantial impact on the exorbitant toll that smoking exerts 
upon the healthcare system. In actual clinical practice, only 13% of 
physicians routinely refer smokers for treatment with 33% report-
ing a lack of confidence in their ability to monitor treatment (27). 
As a result, millions of smoking-induced cases of heart disease, 
diabetes, and cancer occur that could otherwise be prevented 
costing hundreds of billions of dollars and untold human misery.
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Before this goal can be realized, it will be important to better 
understand the dynamic relationship of cg05575921 response to 
smoking. To accomplish this task and avert the potential impact 
of recall bias in cross-sectional studies, prospective longitudinal 
studies of subjects as they enter and exit periods of smoking will 
be necessary to fully understand the response characteristics 
at AHRR. For example, although for the sake of simplicity, we 
have modeled the methylation reversion curve as linear, careful 
scrutiny of the points in Figure  1 will show that this may be 
an oversimplification. Indeed, in our unpublished results from 
a 2013 examination of 19-year-old subjects, there was a trend 
for an overcorrection or hyper-methylation of cg05575921 to 
occur after smoking cessation in these young subjects (28). 
Additionally, it should be clear from the present work and the 
prior work of several groups that both current and past history 
of smoking does not fully explain the magnitude of the demeth-
ylation response at cg05575921 (17, 25, 29). Therefore, in order 
to adjust therapy in the first 2  months of smoking cessation 
therapy, which is the portion most critical to cessation efforts, 
it is absolutely essential to gather additional data points during 
this period of treatment and more fully understand the environ-
mental, behavioral, and genetic factors that can influence the 
rate of cg05575921 change.
This study replicates and extends prior findings showing that 
self-report is an unreliable method for determining smoking 
cessation success (7). Our exit study confirms prior data show-
ing that patients often feel uncomfortable when discussing their 
smoking habits with their physicians. This was borne out in our 
objective analyses. In our study, 11 subjects reported cessation of 
smoking at the 6-month time point, but only six had confirma-
tory serum cotinine and CO levels. Since each of the subjects 
was compensated for their efforts whether or not they achieved 
their personal treatment goals, there was no financial incentive 
for reporting cessation. In fact, as part of the consent process, it 
was carefully explained to the subjects that we would be checking 
CO status at each appointment. Since the bogus pipeline effect 
would predict that conducting CO testing should reduce false 
reporting (30), the rate of false report in general practice may be 
even higher.
Developing relatively fool proof methods of detecting smoking 
and changes in smoking patterns may be particularly important 
for efforts to increase the success rate of cessation programs by 
using financial rewards. In controlled trials, these incentive plans 
can increase the rate of smoking threefold up to 16% (31, 32). 
If these paradigms could incorporate the most effective cur-
rently available pharmacological treatment approach, combined 
varenicline and nicotine replacement, the rate of quitting could 
be even higher. However, to optimally achieve the full impact 
of financial incentives, reliably rewarding cessation early in the 
course of treatment, including among those ~27% of ex-smokers 
who remain on nicotine replacement long-term (12), is critical. 
Unfortunately, because CO monitoring is insensitive to light 
smoking (9, 10) and the nicotine used in NRT is metabolized to 
cotinine, the two leading approaches to objectively quantifying 
cessation are not useful. However, because nicotine itself does not 
affect cg05575921 methylation status (15, 21) and it is possible to 
quantify partial responses, the use of DNA methylation assessment 
could provide a useful yard stick for determining financial reward 
in contingency-based smoking cessation paradigms.
It is likely that this approach would be acceptable to most 
patients. In previous work, Hetherington and colleagues showed 
that the use of CO monitoring feedback was not only accepted 
by patients but also increased the odds of smoking cessation by 
fourfold (33). In our post study survey, subjects were extremely 
receptive to the use of this technology to assess both smoking 
cessation success and the impact of the success on their per-
sonal health outcomes. This positive attitude toward NextGen 
technology suggests methylation assessments may be a new 
avenue through which to engage patients in their personalized 
healthcare. These assessments may include other health outcomes 
such as the F2RL3 residue referred to as cg03636183, cg05575921 
methylation is linked to adverse cardiac and cancer related out-
comes (34, 35). Through simultaneously measuring methylation 
at AHRR as well as a panel of other loci linked to important health 
outcomes, such as diabetes and obesity (36, 37), it may well be 
that patients will gain additional motivation to collaborate with 
their healthcare providers in optimizing their well-being.
The full facilitation of this clinical engagement will not occur 
in the absence of patient education. Like all humans, patients 
are less likely to accept what they do not understand. In that 
respect, the basis of CO monitoring is readily understood because 
patients understand that tobacco smoke contains CO. By con-
trast, the fundamental mechanisms by which smoking influences 
DNA methylation are not well understood by many even in the 
healthcare community. Furthermore, because DNA methylation 
technologies may be able to measure a wide variety of outcomes 
of potential interest to patients, more in-depth analysis of the 
perceived health care needs of current and potential patients 
could be beneficial. Therefore, patient engagement and education 
should be a part in any future clinical approaches.
In summary, in this communication, we show that methyla-
tion status at cg05575921 can be employed to track progress in 
the process of smoking reduction and cessation, and suggest that 
periodic assessment of changes in methylation and feedback to 
patients may be useful in facilitating smoking cessation therapy. 
Future research designed to incorporate the use of this epigenetic 
tool into treatment is likely to be fruitful.
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